How our Next-Generation Platinum Drugs Will Advance Cancer Care
Platinum drugs are the cornerstone of many therapeutic regimens for solid tumor cancers, but are constrained by dose limiting toxicities and eventual tumor regrowth. While incremental improvements have been made with the introduction of new platinum molecules there remains a significant opportunity to create powerful platinum based cancer medicines with improved tolerability and efficacy and provide enhanced benefits to cancer patients. As more and more cancer therapies combine multiple drugs in treatment regimens, there is a strong need for a platinum medicine that can work more effectively together with immuno-oncology and other cancer treatments.
By taking advantage of emerging insights from cancer biology, genomics and molecular tumor targeting, Placon has created next-generation platinum cancer therapies that are designed to substantially improve the efficacy and side effect profile of today’s platinum medicines that are widely used in cancer treatment. BTP-114 is Placon’s first IND approved clinical candidate positioned to enter human trials that uses Placon’s novel albumin-conjugating platinum-prodrug platform. The platform builds on the breakthroughs in platinum chemistry developed by an industry leading chemistry and biology team as well as the pioneering work of the company’s scientific co-founder, Professor Stephen J. Lippard of the Massachusetts Institute of Technology, who is a world leader in platinum chemistry.
BTP-114, our lead compound, is the first next-generation platinum to arise from our proprietary albumin-conjugating, platinum-prodrug platform. BTP-114 has an approved Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) and is positioned to enter the clinic to begin its Phase I clinical study.
We demonstrated in pre-clinical studies that, once administered, BTP-114 rapidly conjugates to serum albumin in blood through strong covalent bonds, resulting in a substantially increased plasma exposure, long circulating half-life and increased up-take by cancer cells with certain molecular profiles. A 13-fold increase in platinum in tumors is observed following dosing of BTP-114, resulting in improved efficacy in preclinical models of lung and ovarian cancer compared to cisplatin, while also reducing key dose limiting toxicities of cisplatin.
Other Next-Generation Platinum Drugs
In addition to our lead drug candidate, BTP-114, Placon has also applied our albumin-conjugating platinum-prodrug platform to a range of other platinum drug structures. In each case, we are focused on using our unique insights and proprietary platinum chemistry to improve the efficacy and side effect profile of platinum-based medicines to evolve cancer care.
We developing next-generation novel platinum medicines designed to improve the efficacy and side effect profile of today’s cytotoxic medicines that are widely used in cancer treatment. Our albumin-conjugating platinum drug candidates have long circulating half lives and preferentially accumulate in tumors, offering the potential for significantly enhanced tumor growth inhibition and reduced side effects based on preclinical studies. BTP-114 is the company’s lead program and is prepared to enter clinical studies with an approved investigational new drug application (IND) from the U.S. Food and Drug Administration (FDA). Placon will pursue clinical development for BTP-114 in collaboration with a strategic partner or other investors.
If you are interested in learning more about BTP-114 and our other advanced platinum drug candidates, please contact us at BD@placontx.com.